30 closest matches · ranked by relevance
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: Recurrent VH Incidence (Early and Late) — 22.2; 10.8; 32.4; 11.1 Percentage of participants — p=<0.05
Intravitreal Bevacizumab Injection · Pars Plana Vitrectomy · Tractional Retinal Detachment
Primary: Best Corrected Visual Acuity — 1.1; 1.4 LogMar
Central Retinal Vein Occlusion With Macular Edema
Primary: Visual Acuity — 0.32; 0.44 logMAR units
Proliferative Diabetic Retinopathy · Diabetic Traction Retinal Detachment · Vitreous Hemorrhage
Primary: Reoperation — 1; 7 participants — p=0.033
Retinal Detachment · Vitreoretinopathy Proliferative
Primary: The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) — 6 Participants
Age Related Macular Degeneration · Choroidal Neovascularization · Macular Edema
Primary: Visual Acuity: Percentage of Patients Losing 3 or More Lines(15 Letters) of Visual Acuity From Baseline. — 80; 90 percent of participants
Neovascular Age-related Macular Degeneration
Primary: Vision — 0.16 logMAR
Diabetes Mellitus · Macular Edema
Primary: Change From Baseline in BCVA (Best Corrected Visual Acuity) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 52 - Last Observation…
Retinopathy of Prematurity
Primary: Number of Participants With Successful Treatment of ROP — 11; 14; 21; 9 Participants
Branch Retinal Vein Occlusion
Primary: Changes of Central Retinal Thickness — 510.35; 468.22; 291.48; 233.33 micrometer — p=0.60
Branch Retinal Vein Occlusion · Central Retinal Vein Occlusion · Macular Edema
Primary: Mean Change From Baseline BCVA — 14; 5 Letters (ETDRS chart)
Diabetic Macular Edema
Primary: Reduction in Macular Edema — 15; 8; 4 Participants
Diabetic Macular Edema
Primary: Efficacy of the Treatment Assessed With Visual Acuity Measured by ETDRS Charts. — 0.18; 0.36; 0.18 logMAR
Vitreous Hemorrhage
Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants
Retinal Detachment · Proliferative Vitreoretinopathy
Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants
Diabetic Macular Edema
Primary: Maximum Concentration (Cmax) of Anti-VEGF Antibody — 25.22; 9.56 ng/mL
Age-Related Macular Degeneration · Macular Degeneration
Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters
Pterygium
Primary: The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. — 5.75 area in millimeters squared…
Non-Ischemic Central Retinal Vein Occlusion
Primary: The Primary Efficacy Endpoint is the Total Number of PRN Bevacizumab Intravitreal Injections Through 24 Weeks — 5; 19; 13; 11 Participants — p=0.00002
Diabetic Retinopathy · Macular Edema
Primary: Efficacy of Treatment Outcomes by Change in Visual Acuity From Baseline — 69.95; 74 letters
Neovascular Age-Related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 12 — 5.2; 5.6; 5.4…
Macular Edema Secondary to Branch Retinal Vein Occlusion
Primary: Average Change in Best Corrected Visual Acuity (BCVA) From Baseline to Month 1 Through Month 6 — 12.5; 5.0 Letters — p=<0.001
Adverse Effect of Radiation Therapy
Primary: Mean Best Corrected Visual Acuity (BCVA) in Patients Treated With Intravitreal Aflibercept Injections for the Management of Radiation Maculopathy. — 0.425; 0.548 Log MAR…
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Primary: Total Number of Intravitreal Injections Over a 12 Month Period — 8.7; 9.5 injections
Uveal Melanoma
Primary: The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). — 1; 0; 0; 0 participants
Branch Retinal Vein Occlusion
Primary: Participants Who Gained at Least 15 Letters in Best Corrected Visual Acuity (BCVA) at Week 24 - LOCF — 24; 48 participants — p=0.0003
Corneal Neovascularization
Primary: Adverse Events (Ocular and Systemic) — 0 participants
Neovascular Glaucoma
Primary: Incidence of Adverse Events — 3; 4 Participants
Retinal Detachment · Diabetic Retinopathy
Primary: The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction…
Macular Degeneration
Primary: The Percentage of Patients With Less Than 15 Letters of ETDRS Visual Loss at 12 Months. — 22; 14 percentage of participants